Coprescription of mood stabilizers in schizophrenia, dosing, and clinical correlates: An international study.
Saved in:
| Title: | Coprescription of mood stabilizers in schizophrenia, dosing, and clinical correlates: An international study. |
|---|---|
| Authors: | Lim, Wai Kwong (AUTHOR), Chew, Qian Hui (AUTHOR), He, Yan‐Ling (AUTHOR), Si, Tian‐Mei (AUTHOR), Chiu, Fung‐Kum Helen (AUTHOR), Xiang, Yu‐Tao (AUTHOR), Kato, Takahiro A. (AUTHOR), Kanba, Shigenobu (AUTHOR), Shinfuku, Naotaka (AUTHOR), Lee, Min‐Soo (AUTHOR), Park, Seon‐Cheol (AUTHOR), Park, Yong‐Chon (AUTHOR), Chong, Mian‐Yoon (AUTHOR), Lin, Shih‐Ku (AUTHOR), Yang, Shu‐Yu (AUTHOR), Tripathi, Adarsh (AUTHOR), Avasthi, Ajit (AUTHOR), Grover, Sandeep (AUTHOR), Kallivayalil, Roy Abraham (AUTHOR), Udomratn, Pichet (AUTHOR) |
| Source: | Human Psychopharmacology: Clinical & Experimental. Nov2020, Vol. 35 Issue 6, p1-7. 7p. |
| Subjects: | Mood stabilizers, Aripiprazole, Schizophrenia, Body mass index, Psychoses, Amisulpride, Symptoms |
| Geographic Terms: | Asia |
| Abstract: | Objective: Studies examining coprescription and dosages of mood stabilizers (MSs) with antipsychotics for psychotic disorders are infrequent. Based on sparse extant data and clinical experience, we hypothesized that adjunctive MS use would be associated with certain demographic (e.g., younger age), clinical factors (e.g., longer illness duration), and characteristics of antipsychotic treatment (e.g., multiple or high antipsychotic doses). Methods: Within an Asian research consortium focusing on pharmaco‐epidemiological factors in schizophrenia, we evaluated rates of MS coprescription, including high doses (>1000 mg/day lithium‐equivalents) and clinical correlates. Results: Among 3557 subjects diagnosed with schizophrenia in 14 Asian countries, MSs were coprescribed with antipsychotics in 13.6% (n = 485) of the sample, with 10.9% (n = 53) on a high dose. Adjunctive MS treatment was associated (all p < 0.005) with demographic (female sex and younger age), setting (country and hospitalization), illness (longer duration, more hospitalizations, non‐remission of illness, behavioral disorganization, aggression, affective symptoms, and social–occupational dysfunction), and treatment‐related factors (higher antipsychotic dose, multiple antipsychotics, higher body mass index, and greater sedation). Patients given high doses of MSs had a less favorable illness course, more behavioral disorganization, poorer functioning, and higher antipsychotic doses. Conclusions: Schizophrenia patients receiving adjunctive MS treatment in Asian psychiatric centers are more severely ill and less responsive to simpler treatment regimens. [ABSTRACT FROM AUTHOR] |
| Copyright of Human Psychopharmacology: Clinical & Experimental is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
